Sunitinib in Treating Patients With Idiopathic Myelofibrosis
Status:
Terminated
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sunitinib works in treating patients with idiopathic
myelofibrosis. Sunitinib may stop the growth of abnormal cells by blocking some of the
enzymes needed for cell growth and by blocking blood flow to the abnormal cells.